Home Biosimilar Antibodies Protein Tyrosine Kinase VEGFR Ranibizumab (Anti-VEGFA)
For research use only. Not for use in humans.

Ranibizumab (Anti-VEGFA)

Synonyms: Lucentis

Ranibizumab (Anti-VEGFA) is a recombinant humanized IgG1 monoclonal antibody fragment that inhibits (VEGF-A) and degrades angiogenesis throughout the body and in the eye also interrupts the interaction of VEGF with its receptors, and thus prevents the subsequent growth of new blood vessels.

Ranibizumab (Anti-VEGFA)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A230501 Purity: 99% Protein concentration: 3.61mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation VEGFR1 VEGFR2 VEGFR3 VEGFR VEGF Others
Foretinib 94 Met,Tie-2,RON
Cediranib (AZD2171) 67 c-Kit,PDGFRβ,FGFR1
PD173074 124 FGFR1
Dovitinib (TKI-258) 52 FLT3,c-Kit,FGFR1
Linifanib (ABT-869) 33 CSF-1R,FLT3,Kit
Vatalanib (PTK787) 2HCl 53 PDGFRβ,c-Kit,c-Fms
RAF265 (CHIR-265) 24 B-Raf
Motesanib Diphosphate (AMG-706) 12 Kit,RET,PDGFR
Brivanib (BMS-540215) 10 FGFR1
MGCD-265 analog 12 Met,RON,Tie-2
AEE788 (NVP-AEE788) 13 EGFR,HER2/ErbB2,c-Abl
ENMD-2076 9 FLT3,RET,Aurora A
OSI-930 7 CSF-1R,LCK,C-Raf
CYC116 10 Aurora A,Aurora B,FLT3
Ki8751 21 c-Kit,PDGFRα
Telatinib 5 c-Kit,PDGFRα
PP121 5 PDGFR,Hck,mTOR
KRN 633 6 PDGFRα,c-Kit,BTK
SAR131675 34
Apatinib (YN968D1) mesylate 26 RET
BMS-794833 2 Met
Brivanib Alaninate (BMS-582664) 2 FGFR1
Golvatinib (E7050) 8 c-Met
Semaxanib (SU5416) 21
ZM 323881 HCl 20
ZM 306416 13 Src,Abl
R1530 0 FGFR1
Chiauranib 0 c-Kit,CSF-1R,Aurora B
Emvododstat (PTC299) 0 Dihydroorotate dehydrogenase
XL092 0 AXL,MER,MET
Lucitanib (E3810) hydrochloride 1 FGFR1,FGFR2
Ningetinib 0 Axl,c-Met
Ki20227 1 c-Fms,PDGFRβ,c-Kit
Tyrphostin AG1433 0 PDGFRβ
SU14813 2 PDGFRβ,KIT
Sulfatinib 1 CSF1R,FGFR1
CS-2660 (JNJ-38158471) 0 RET,Kit
SU5204 1 HER2
SU5214 0 EGFR
SU5205 0
SU5408 2
Pamufetinib (TAS-115) 0 recombinant MET
ODM-203 0 FGFR3,FGFR1,FGFR2
WHI-P180 0 RET
Altiratinib 3 MET Y1230C,TrkA,TrkC
Motesanib (AMG-706) 11 c-Kit,c-Ret,PDGFR
Fruquintinib (HMPL-013) 6
Apatinib (YN968D1) 28 RET
Cediranib Maleate 14 c-Kit,PDGFRβ,FGFR1
Toceranib phosphate 1 PDGFR
Anlotinib (AL3818) Dihydrochloride 48 c-Kit
Sitravatinib (MGCD516) 7 DDR2,EPHA3,Axl
BFH772 0
BAW2881 (NVP-BAW2881) 3 C-Raf-1,B-RAFV599E,c-Abl
SU 5402 24 FGFR1,PDGFRβ
Dovitinib (TKI258) Lactate monohydrate 31 FLT3,c-Kit,FGFR1
LY2874455 15 FGFR2,FGFR1,FGFR4
SKLB1002 5
AZD2932 3 PDGFRβ,Flt3,c-Kit
WAY-340935 0
hVEGF-IN-1 0
4SC-203 0
Chebulinic acid 0
Nastorazepide 0
Vorolanib 0 PDGFR
MAZ51 1 RhoA,GSK3β,Akt
SU5208 0
SU5614 3 FLT3,c-Kit,RET
AG-13958 0
SKLB 610 2 FGFR2,PDGFR
SU1498 2
ZD-4190 0 Flt-1
PDGFR inhibitor 1 4 PDGFR,Kit,c-Fms
Taxifolin (Dihydroquercetin) 4
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ranibizumab (Anti-VEGFA) is a recombinant humanized IgG1 monoclonal antibody fragment that inhibits (VEGF-A) and degrades angiogenesis throughout the body and in the eye also interrupts the interaction of VEGF with its receptors, and thus prevents the subsequent growth of new blood vessels.

Product Details

CAS No. 347396-82-1
Molecular Weight 49.19 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.